Search

everythinglearnresearchcommunity

for

Search:↓

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Belimumab effectively controls SLE disease activity and reduces steroid use.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Infliximab may cause hair loss in Crohn's disease patients.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Dupilumab effectively treats severe skin issues in a rare genetic disorder.

Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Adalimumab helped control a child's severe eye disease when other treatments failed.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.